Environmental and biological monitoring of antineoplastic drugs in four workplaces in a Swedish hospital

International Archives of Occupational and Environmental Health

Volumn 81, Issue 7, 2008, Pages 899-911

  Hedmer, Maria ^a   Tinnerberg, H ^a   Axmon, A ^a   Jonsson B A G ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antineoplastic drugs; Biological monitoring; Occupational exposure; Variability; Wipe sampling

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; IFOSFAMIDE;

ARTICLE; BIOLOGICAL MONITORING; CONTAMINATION; ENVIRONMENTAL MONITORING; HEALTH CARE PERSONNEL; HUMAN; LIQUID CHROMATOGRAPHY; OCCUPATIONAL EXPOSURE; ONCOLOGY WARD; OUTPATIENT; PHARMACY; PROTECTIVE CLOTHING; SWEDEN; TANDEM MASS SPECTROMETRY; UNIVERSITY HOSPITAL; URINALYSIS; WORKPLACE;

ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, LIQUID; CYCLOPHOSPHAMIDE; ENVIRONMENTAL MONITORING; HOSPITALS; HUMANS; IFOSFAMIDE; MASS SPECTROMETRY; OCCUPATIONAL EXPOSURE; PERSONNEL, HOSPITAL; PHARMACIES; SWEDEN; WORKPLACE;

EID: 42549094691     PISSN: 03400131     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00420-007-0284-y     Document Type: Article

References (60)

1. Acampora A, Castiglia L, Miraglia N, Pieri M, Soave C, Liotti F, Sannolo N (2005) A case study: Surface contamination of cyclophosphamide due to working practices and cleaning procedures in two Italian hospitals. Ann Occup Hyg 49:611-618
2. Boddy AV, Yule SM (2000) Metabolism and pharmacokinetics of oxazaphosphorines. Clin Pharmacokinet 38:291-304
3. Burgaz S, Karahalil B, Canhi Z, Terzioglu F, Ancel G, Anzion RB, Bos RP, Huttner E (2002) Assessment of genotoxic damage in nurses occupationally exposed to antineoplastics by the analysis of chromosomal aberrations. Hum Exp Toxicol 21:129-135
4. Buringh E, Lanting R (1991) Exposure variability in the workplace: Its implications for the assessment of compliance. Am Ind Hyg Assoc J 52:6-13
5. Cavallo D, Ursini CL, Perniconi B, Francesco AD, Giglio M, Rubino FM, Marinaccio A, Iavicoli S (2005) Evaluation of genotoxic effects induced by exposure to antineoplastic drugs in lymphocytes and exfoliated buccal cells of oncology nurses and pharmacy employees. Mutat Res 587:45-51
6. Connor TH, Anderson RW, Sessink PJ, Broadfield L, Power LA (1999a) Surface contamination with antineoplastic agents in six cancer treatment centers in Canada and the United States. Am J Health Syst Pharm 56:1427-1432
7. Connor TH (1999b) Permeability of nitrile rubber, latex, polyurethane, and neoprene gloves to 18 antineoplastic drugs. Am J Health Syst Pharm 56:2450-2453
8. Crauste-Manciet S, Sessink PJ, Ferrari S, Jomier JY, Brossard D (2005) Environmental contamination with cytotoxic drugs in healthcare using positive air pressure isolators. Ann Occup Hyg 49:619-628
9. Dranitsaris G, Johnston M, Poirier S, Schueller T, Milliken D, Green E, Zanke B (2005) Are health care providers who work with cancer drugs at an increased risk for toxic events? A systematic review and meta-analysis of the literature. J Oncol Pharm Pract 11:69-78
10. Ensslin AS, Stoll Y, Pethran A, Pfaller A, Römmelt H, Fruhmann G (1994) Biological monitoring of cyclophosphamide and ifosfamide in urine of hospital personnel occupationally exposed to cytostatic drugs. Occup Environ Med 51:229-233
11. Evelo CT, Bos RP, Peters JG, Henderson PT (1986) Urinary cyclophosphamide assay as a method for biological monitoring of occupational exposure to cyclophosphamide. Int Arch Occup Environ Health 58:151-155
12. Fenske RA, Curry PB, Wandelmaier F, Ritter L (1991) Development of dermal and respiratory sampling procedures for human exposure to pesticides in indoor environments. J Expo Anal Environ Epidemiol 1:11-30
13. Floridia L, Pietropaolo AM, Tavazzani M, Rubino FM, Colombi A (1999) High-performance liquid chromatography of methotrexate for environmental monitoring of surface contamination in hospital departments and assessment of occupational exposure. J Chromatogr B Biomed Sci Appl 726:95-103
14. Fransman W, Vermeulen R, Kromhout H (2005) Dermal exposure to cyclophosphamide in hospitals during preparation, nursing and cleaning activities. Int Arch Occup Environ Health 78:403-412
15. Fransman W, Roeleveld N, Peelen S, de Kort W, Kromhout H, Heederik D (2007a) Nurses with dermal exposure to antineoplastic drugs: reproductive outcomes. Epidemiology 18:112-119
16. Fransman W, Peelen S, Hilhorst S, Roeleveld N, Heederik D, Kromhout H (2007b) A pooled analysis to study trends in exposure to antineoplastic drugs among nurses. Ann Occup Hyg 51:231-239
17. Fuchs J, Hengstler JG, Jung D, Hiltl G, Konietzko J, Oesch F (1995) DNA damage in nurses handling antineoplastic agents. Mutat Res 342:17-23
18. Hedmer M, Jönsson BAG, Nygren O (2004) Development and validation of methods for environmental monitoring of cyclophosphamide in workplaces. J Environ Monit 6:979-984
19. Hedmer M, Georgiadi A, Rämme Bremberg E, Jönsson BAG, Eksborg S (2005) Surface contamination of cyclophosphamide packaging and surface contamination with antineoplastic drugs in a hospital pharmacy in Sweden. Ann Occup Hyg 49:629-637
20. Hedmer M, Höglund P, Cavallin-Ståhl E, Albin M, Jönsson BAG (2008) Validation of urinary excretion of cyclophosphamide as a biomarker of exposure by studying its renal clearance at high and low plasma concentrations in cancer patients. Int Arch Occup Environ Health 81:285-293
21. IARC (1981) monographs on the evaluation of the carcinogenic risk of chemicals to humans, vol 26. Some antineoplastic and immunosuppressive agents. International Agency for Research on Cancer, Lyon
22. IARC (1987) monographs on the evaluation of the carcinogenic risk to humans, suppl 7. Overall evaluation of carcinogenicity: An updating of IARC monographs volumes 1-42. International Agency for Research on Cancer, Lyon
23. IARC (1990) monographs on the evaluation of the carcinogenic risk to humans, vol 50. Pharmaceutical drugs. International Agency for Research on Cancer, Lyon
24. Kiffmeyer TK, Kube C, Opiolka S, Schmidt KG, Schöppe G, Sessink PJM (2002) Vapour pressures, evaporation behaviour and airborne concentrations of hazardous drugs; implications for occupational safety. Pharm J 268:331-337
25. Kromhout H, Hoek F, Uitterhoeve R, Huijbers R, Overmars RF, Anzion R, Vermeulen R (2000) Postulating a dermal pathway for exposure to anti-neoplastic drugs among hospital workers. Applying a conceptual model to the results of three workplace surveys. Ann Occup Hyg 44:551-560
26. Krstev S, Perunicic B, Vidakovic A (2003) Work practice and some adverse health effects in nurses handling antineoplastic drugs. Med Lav 94:432-439
27. Laidlaw JL, Connor TH, Theiss JC, Anderson RW, Matney TS (1984) Permeability of latex and polyvinyl chloride gloves to 20 antineoplastic drugs. Am J Hosp Pharm 41:2618-2623
28. Leidel NA, Busch KA, Crouse WE (1975) Exposure measurement action level and occupational environmental variability. DHEW (NIOSH) Pub. No. 76-131; NTIS Pub. No. PB-267-509. US National Technical Information Service, Springfield, VA, USA
29. Mason H, Sams C, Jones K, Cairns W (2001) Cytotoxic drug exposure in two pharmacies using positive and negative pressure enclosures for the formulation of cytotoxic drugs, Report no. HEF01/01: 1-42. Sheffield: Health and Safety Laboratory
30. Mason HJ, Morton J, Garfitt SJ, Iqbal S, Jones K (2003) Cytotoxic drug contamination on the outside of vials delivered to a hospital pharmacy. Ann Occup Hyg 47:681-685
31. Mason HJ, Blair S, Sams C, Jones K, Garfitt SJ, Cuschieri MJ, Baxter PJ (2005) Exposure to antineoplastic drugs in two UK hospital pharmacy units. Ann Occup Hyg 49:603-610
32. McDevitt JJ, Lees PS, McDiarmid MA (1993) Exposure of hospital pharmacists and nurses to antineoplastic agents. J Occup Med 35:57-60
33. Meijster T, Fransman W, Veldhof R, Kromhout H (2006) Exposure to antineoplastic drugs outside the hospital environment. Ann Occup Hyg 50:657-664
34. Minoia C, Turci R, Sottani C, Schiavi A, Perbellini L, Angeleri S, Draicchio F, Apostoli P (1998) Application of high performance liquid chromatography/tandem mass spectrometry in the environmental and biological monitoring of health care personnel occupationally exposed to cyclophosphamide and ifosfamide. Rapid Commun Mass Spectrom 12:1485-1493
35. Peretz C, Goldberg P, Kahan E, Grady S, Goren A (1997) The variability of exposure over time: A prospective longitudinal study. Ann Occup Hyg 41:485-500
36. Pethran A, Schierl R, Hauff K, Grimm CH, Boos KS, Nowak D (2003) Uptake of antineoplastic agents in pharmacy and hospital personnel. Part I: monitoring of urinary concentrations. Int Arch Occup Environ Health 76:5-10
37. Rappaport SM (1991) Assessment of long-term exposures to toxic substances in air. Ann Occup Hyg 35:61-121
38. Ringborg U, Henriksson R, Friberg S (1998) Onkologi [Oncology]. Liber, Stockholm
39. Roberts S, Khammo N, McDonnell G, Sewell GJ (2006) Studies on the decontamination of surfaces exposed to cytotoxic drugs in chemotherapy workstations. J Oncol Pharm Pract 12:95-104
40. Rubino FM, Floridia L, Pietropaolo AM, Tavazzani M, Colombi A (1999) Measurement of surface contamination by certain antineoplastic drugs using high-performance liquid chromatography: Applications in occupational hygiene investigations in hospital environments. Med Lav 90:572-583
41. Schmaus G, Schierl R, Funck S (2002) Monitoring surface contamination by antineoplastic drugs using gas chromatography-mass spectrometry and voltammetry. Am J Health Syst Pharm 59:956-961
42. Schulz H, Bigelow S, Dobish R, Chambers CR (2005) Antineoplastic agent workplace contamination study: The Alberta cancer board pharmacy perspective. J Oncol Pharm Pract 11:101-109
43. Selevan SG, Lindbohm ML, Horung RW, Hemminki K (1985) A study of occupational exposure to antineoplastic drugs and fetal loss in nurses. N Engl J Med 313:1173-1178
44. Sessink PJ, Boer KA, Scheefhals AP, Anzion RB, Bos RP (1992a) Occupational exposure to antineoplastic agents at several departments in a hospital. Environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers. Int Arch Occup Environ Health 64:105-112
45. Sessink PJ, Anzion RB, Van den Broek PH, Bos RP (1992b) Detection of contamination with antineoplastic agents in a hospital pharmacy department. Pharm Weekbl Sci 14:16-22
46. Sladek NE (1994) Metabolism and pharmacokinetic behavior of cyclophosphamide and related oxazaphosphorines. In: Powis G (ed) Anticancer drugs:rEactive metabolism and drug interactions. Pergamon Press, Oxford
47. Soule RD (1991) Industrial hygiene sampling and analysis. In: Clayton GD, Clayton FE (eds) Patty's industrial hygiene and toxicology, vol I, Part B, 4th edn. Wiley, NY
48. Stucker I, Caillard JF, Collin R, Gout M, Poyen D, Hemon D (1990) Risk of spontaneous abortion among nurses handling antineoplastic drugs. Scand J Work Environ Health 16:102-107
49. Swedish Work Environment Authority (2005) Cytostatika och andra läkemedel med bestående toxisk effekt [Cytostatics and other drugs with permanent toxic effects]. AFS 2005:5, Solna, Sweden
50. Turci R, Sottani C, Ronchi A, Minoia C (2002) Biological monitoring of hospital personnel occupationally exposed to antineoplastic agents. Toxicol Lett 134:57-64
51. Turci R, Sottani C, Spagnoli G, Minoia C (2003) Biological and environmental monitoring of hospital personnel exposed to antineoplastic agents: A review of analytical methods. J Chromatogr B Analyt Technol Biomed Life Sci 789:169-209
52. Turci R, Minoia C (2006) Residual hazard assessment related to handling of antineoplastic drugs: Safety system evolution and quality assurance of analytical measurement. Ann N Y Acad Sci 1076:649-656
53. Undeger U, Basaran N, Kars A, Guc D (1999) Assessment of DNA damage in nurses handling antineoplastic drugs by the alkaline COMET assay. Mutat Res 439:277-285
54. Valanis BG, Vollmer WM, Labuhn KT, Glass AG (1993a) Association of antineoplastic drug handling with acute adverse effects in pharmacy personnel. Am J Hosp Pharm 50:455-462
55. Valanis BG, Vollmer WM, Labuhn KT, Glass AG (1993b) Acute symptoms associated with antineoplastic drug handling among nurses. Cancer Nurs 16:288-295
56. Valanis B, Vollmer W, Labuhn K, Glass A (1997) Occupational exposure to antineoplastic agents and self-reported infertility among nurses and pharmacists. J Occup Environ Med 39:574-580
57. Valanis B, Vollmer WM, Steele P (1999) Occupational exposure to antineoplastic agents: Self-reported miscarriages and stillbirths among nurses and pharmacists. J Occup Environ Med 41:632-638
58. Vermeulen R, Bos RP, Kromhout H (2001) Mutagenic exposure in the rubber manufacturing industry: An industry wide survey. Mutat Res 490:27-34
59. Wick C, Slawson MH, Jorgenson JA, Tyler LS (2003) Using a closed-system protective device to reduce personnel exposure to antineoplastic agents. Am J Health Syst Pharm 60:2314-2320
60. Ziegler E, Mason HJ, Baxter PJ (2002) Occupational exposure to cytotoxic drugs in two UK oncology wards. Occup Environ Med 59:608-612